Geron Stock Performance
| GERN Stock | USD 1.23 0.01 0.81% |
The company retains a Market Volatility (i.e., Beta) of 1.41, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Geron will likely underperform. At this point, Geron has a negative expected return of -0.11%. Please make sure to check out Geron's value at risk, as well as the relationship between the skewness and day median price , to decide if Geron performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Geron has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Last Split Factor 1058:1000 | Last Split Date 2014-07-22 |
1 | MONDAY INVESTOR DEADLINE Robbins Geller Rudman Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action... | 05/07/2025 |
2 | Geron Faces Downgrade Amid Rytelo Launch Challenges GERN Stock News | 05/08/2025 |
3 | Orbimed Advisors LLC Raises Stock Holdings in Geron Co. | 05/13/2025 |
4 | Acquisition by Spiegel Robert J. of 180000 shares of Geron at 1.34 subject to Rule 16b-3 | 05/21/2025 |
5 | Geron Announces Presentations at ASCO and EHA Underscoring RYTELO Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis ... | 05/28/2025 |
6 | Geron Q1 2025 slides RYTELO growth plans amid revenue challenges By Investing.com - Investing.com Nigeria | 06/09/2025 |
7 | With 65 percent institutional ownership, Geron Corporation is a favorite amongst the big guns | 06/13/2025 |
8 | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 06/18/2025 |
9 | Acquisition by Spiegel Robert J. of 5540 shares of Geron at 1.41 subject to Rule 16b-3 | 06/30/2025 |
10 | Leerink Partners Reiterates a Buy Rating on Geron Corporation | 07/07/2025 |
11 | Goldman Sachs Issues Sell Rating on Geron with Downside Expectation GERN Stock News | 07/10/2025 |
12 | Geron Presents Positive RYTELO Data for LR-MDS at ASCO EHA, Highlights Efficacy, Myelofibrosis Program Progress | 07/15/2025 |
13 | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635 GERN Stock News | 07/18/2025 |
| Begin Period Cash Flow | 71.1 M | |
| Total Cashflows From Investing Activities | -106 M |
Geron Relative Risk vs. Return Landscape
If you would invest 139.00 in Geron on April 23, 2025 and sell it today you would lose (16.00) from holding Geron or give up 11.51% of portfolio value over 90 days. Geron is currently does not generate positive expected returns and assumes 4.2663% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Geron, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Geron Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Geron's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Geron, and traders can use it to determine the average amount a Geron's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0263
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GERN |
Estimated Market Risk
| 4.27 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Geron is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Geron by adding Geron to a well-diversified portfolio.
Geron Fundamentals Growth
Geron Stock prices reflect investors' perceptions of the future prospects and financial health of Geron, and Geron fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Geron Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.20) % | ||||
| Operating Margin | (0.42) % | ||||
| Current Valuation | 514.68 M | ||||
| Shares Outstanding | 636.92 M | ||||
| Price To Earning | (12.48) X | ||||
| Price To Book | 2.94 X | ||||
| Price To Sales | 6.74 X | ||||
| Revenue | 76.99 M | ||||
| Gross Profit | 9.38 M | ||||
| EBITDA | (154.85 M) | ||||
| Net Income | (174.57 M) | ||||
| Cash And Equivalents | 219.29 M | ||||
| Cash Per Share | 0.58 X | ||||
| Total Debt | 121.72 M | ||||
| Debt To Equity | 0.39 % | ||||
| Current Ratio | 4.85 X | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (218.62 M) | ||||
| Earnings Per Share | (0.21) X | ||||
| Market Capitalization | 783.41 M | ||||
| Total Asset | 594.46 M | ||||
| Retained Earnings | (1.77 B) | ||||
| Working Capital | 402.69 M | ||||
| Current Asset | 115.89 M | ||||
| Current Liabilities | 6.63 M | ||||
About Geron Performance
By examining Geron's fundamental ratios, stakeholders can obtain critical insights into Geron's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Geron is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 10.1 K | 10.6 K | |
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.62) | (0.65) |
Things to note about Geron performance evaluation
Checking the ongoing alerts about Geron for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Geron help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Geron generated a negative expected return over the last 90 days | |
| Geron may become a speculative penny stock | |
| Geron has high historical volatility and very poor performance | |
| Geron has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 76.99 M. Net Loss for the year was (174.57 M) with profit before overhead, payroll, taxes, and interest of 9.38 M. | |
| Geron currently holds about 219.29 M in cash with (218.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.58. | |
| Over 81.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635 GERN Stock News |
- Analyzing Geron's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Geron's stock is overvalued or undervalued compared to its peers.
- Examining Geron's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Geron's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Geron's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Geron's stock. These opinions can provide insight into Geron's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.21) | Revenue Per Share | Quarterly Revenue Growth 129.273 | Return On Assets | Return On Equity |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.